Trial Profile
A phase II study of radiation with concomitant and then sequential temozolomide in patients with newly diagnosed supratentorial malignant glioma who have undergone surgery with Gliadel wafer [carmustine polifeprosan 20 wafer] insertion
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2009
Price :
$35
*
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary) ; Temozolomide
- Indications Glioma
- Focus Therapeutic Use
- 09 Sep 2009 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 30 Oct 2007 Status changed from recruiting to in progress.
- 22 Nov 2006 11th Annual Meeting of the Society for Neuro-Oncology (SNO).